Alerts will be sent to your verified email
Verify Email
CHCL
|
Cian Healthcare
|
Rekvina Laboratories
|
Venmax Drugs&Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
1.01 % | 9.93 % | 1.17 % |
|
5yr average Equity Multiplier
|
3.21 | 6.31 | 0.08 |
|
5yr Average Asset Turnover Ratio
|
0.39 | 0.0 | 0.14 |
|
5yr Avg Net Profit Margin
|
-17.41 % | 0.0 | -19.62 % |
|
Price to Book
|
0.0 | 0.0 | 1.49 |
|
P/E
|
0.0 | 0.0 | 85.63 |
|
5yr Avg Cash Conversion Cycle
|
55.28 Days | 0.0 | 288.55 Days |
|
Inventory Days
|
219.95 Days | 0.0 | 5.2 Days |
|
Days Receivable
|
224.43 Days | 0.0 | 430.69 Days |
|
Days Payable
|
542.88 Days | 0.0 | 141.12 Days |
|
5yr Average Interest Coverage Ratio
|
-0.81 | -132.32 | -260.56 |
|
5yr Avg ROCE
|
-0.26 % | -100.9 % | -47.43 % |
|
5yr Avg Operating Profit Margin
|
7.22 % | 0.0 | -65.91 % |
|
5 yr average Debt to Equity
|
1.21 | -0.19 | -0.45 |
|
5yr CAGR Net Profit
|
n/a | 18.47 % | -42.57 % |
|
5yr Average Return on Assets
|
-3.63 % | -132.46 % | 199.45 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
95.0 % | 41.3 % | 13.8 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
28.74 % | 0.0 | -9.33 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Cian Healthcare
|
Rekvina Laboratories
|
Venmax Drugs&Pharma
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|